サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1108456

RNAベースの治療薬およびワクチンの世界市場：ポストCOVID時代がRNAベースの治療薬およびワクチンに関する広範な研究を強化

Global Market Study on RNA-based Therapeutics and Vaccines: Post Covid-era to bolster extensive research pertaining to RNA-based therapeutics and vaccines
出版日: | 発行: Persistence Market Research | ページ情報: 英文 177 Pages | 納期: 2～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
RNAベースの治療薬およびワクチンの世界市場：ポストCOVID時代がRNAベースの治療薬およびワクチンに関する広範な研究を強化
出版日: 2022年05月23日
発行: Persistence Market Research
ページ情報: 英文 177 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のRNAベースの治療薬およびワクチン市場について調査し、製品タイプ別、適応症タイプ別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場イントロダクション

第3章 RNAベースの治療薬およびワクチンの市場機会分析

  • マクロ経済要因
  • 機会分析

第4章 市場の背景

  • 規制シナリオ
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会分析
  • パイプライン評価

第5章 国内総生産： 地域別および国別

第6章 北米のRNAベースの治療薬およびワクチン市場の機会評価

第7章 ラテンアメリカのRNAベースの治療薬およびワクチン市場の機会評価

第8章 欧州のRNAベースの治療薬およびワクチン市場の機会評価

第9章 アジア太平洋のRNAベースの治療薬およびワクチン市場の機会評価

第10章 中東およびアフリカRNAベースの治療薬およびワクチン市場の機会評価

第11章 競合分析

  • 競合ダッシュボード

第12章 企業プロファイル

  • 会社の詳細
    • Alnylam Pharmaceuticals, Inc.
    • Arbutus Biopharma Corp.
    • Arrowhead Pharmaceuticals, Inc.
    • BioNTech AG
    • CureVac AG
    • Dicerna Pharmaceuticals, Inc.
    • Regulus Therapeutics, Inc.
    • Marina Biotech, Inc.
    • miRagen Therapeutics
    • Moderna Therapeutics, Inc.
    • Quark Pharmaceuticals, Inc.
    • Santaris Pharma A/S（A Roche Company）
    • Sylentis S.A.

第13章 世界のRNAベースの治療薬およびワクチン市場の機会評価：地域別

  • イントロダクション/主な調査結果
  • 市場の機会評価： 地域別
    • 北米
    • ラテンアメリカ
    • 欧州
    • 中国を除くアジア太平洋
    • 中東・アフリカ
    • 中国
  • 市場魅力度分析：地域別

第14章 世界のRNAベースの治療薬およびワクチン市場の機会評価：製品タイプ別

  • イントロダクション/主な調査結果
  • 市場および数量の機会評価：製品タイプ別
    • RNAベースの治療法
    • RNAベースのワクチン
  • 市場魅力分析：製品タイプ別

第15章 世界のRNAベースの治療薬およびワクチン市場の機会評価： 適応症タイプ別

  • イントロダクション/主な調査結果
  • 市場および数量の機会評価： 適応症タイプ別
    • 腫瘍学
    • 免疫学
    • 眼科
    • 心血管疾患
    • 感染症
    • 遺伝病
    • その他
  • 市場魅力度分析：適応症別

第16章 世界の製品機会評価

第17章 仮定と頭字語の使用

第18章 調査手法

図表

List of Tables

  • Table 1: Expenditure on Health, (% of GDP), by Country, 2013 - 2021
  • Table 2: Expenditure on Health, (% of GDP), by Country, 2013 - 2021
  • Table 3: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country
  • Table 4: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
  • Table 5: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication
  • Table 6: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
  • Table 7: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication
  • Table 8: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country
  • Table 9: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
  • Table 10: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication
  • Table 11: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Country
  • Table 12: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
  • Table 13: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Indication
  • Table 14: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Product Type
  • Table 15: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Indication
  • Table 16: Competitive Scenario for Hereditary ATTR Amyloidosis (Patisiran (ALN-TTR02))
  • Table 17: Competitive Scenario for Hemophilia A Fitusiran (ALN-AT3SC)
  • Table 18: Competitive Scenario for Hypercholesterolemia (Inclisiran)
  • Table 19: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Region
  • Table 20: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment, 2022-2028, By Product Type
  • Table 21: Global RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis & Opportunity Assessment 2022-2028, By Indication

List of Figures

  • Figure 1: Estimated/Actual launching of RNA Therapeutics and Vaccines and their Impact on market
  • Figure 2: Global RNA based Vaccines Pipeline Assessment: By Development Phase
  • Figure 3: Global RNA based Vaccines Pipeline Assessment: By Disease Indication
  • Figure 4: Global RNA based Therapeutics Pipeline Assessment: By Development Phase
  • Figure 5: Global RNA based Therapeutics Pipeline Assessment: By Disease Indication
  • Figure 6: North America RNA-based Therapeutics and Vaccines Market Share, By Country (2022)
  • Figure 7: North America RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2022 & 2028
  • Figure 8: North America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028
  • Figure 9: Latin America RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028
  • Figure 10: Europe RNA-based Therapeutics and Vaccines Market Share, By Country (2022)
  • Figure 11: Europe RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2022 & 2028
  • Figure 12: Europe RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028
  • Figure 13: Asia Pacific RNA-based Therapeutics and Vaccines Market Share, By Country (2022)
  • Figure 14: Asia Pacific RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2022 & 2028
  • Figure 15: Asia Pacific RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028
  • Figure 16: Middle East & Africa RNA-based Therapeutics and Vaccines Market Size (US$ Mn) Analysis, 2022-2028
  • Figure 17: Global RNA-based Therapeutics and Vaccines Market Share, By Region (2028)
  • Figure 18: Global RNA-based Therapeutics and Vaccines Market size (US$ Mn) 2022 & 2028, By Region
  • Figure 19: Global RNA-based Therapeutics and Vaccines Market Share, By Product Type (2028)
  • Figure 20: Global RNA-based Therapeutics and Vaccines Market Share, By RNA-based Therapeutics segment (2028)
  • Figure 21: Global RNA-based Therapeutics and Vaccines Market Share, By Indication (2028)
  • Figure 22: Global RNA-based Therapeutics and Vaccines Market Value Analysis and Opportunity Assessment, 2022-2028 (US$ Mn)
  • Figure 23: Global RNA-based Therapeutics and Vaccines Market Absolute $ Opportunity (US$ Mn), 2022-2028
目次
Product Code: PMRREP12868

RNA-Based Therapeutics and Vaccines Market Analysis 2022-2028

A recent market study published by Persistence Market Research (PMR) on the RNA-Based Therapeutics and Vaccines Market including global industry analysis for 2013-2021 & opportunity assessment for 2022-2028, delivers a comprehensive assessment of the most important market dynamics. After conducting a thorough research on the historical as well as current growth parameters of the market, growth prospects are obtained with utmost precision.

RNA-Based Therapeutics and Vaccines Market: Segmentation

The global RNA-Based Therapeutics and Vaccines Market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Product Type

Workstations

Reagents and Consumables

Kits (RNA sample preparation and DNA sample preparation)

Application

Research Applications

Diagnostic Testing

Clinical Testing

End User

Diagnostic Centers

Hospitals

Academic & Research Institutes

Forensic Science Laboratories

CROs (Contract Research Organizations)

Region

North America

Latin America

Europe

East Asia

South Asia

Oceania

Middle East & Africa (MEA)

Key Questions Answered in Report

The research study offers inclusive insights about the growth of the market in the most comprehensive manner. Key insights offered in the report answer some of the most salient questions that assist stakeholders in gauging all the emerging possibilities.

What are the key trends that are continuously shaping market growth?

Which are the prominent regions that offer plentiful opportunities for players in the market?

How has the outbreak of COVID-19 affected the market and what would the trend be like during the forecast period?

What are the differential strategies adopted by key players to hold a significant share in the RNA-Based Therapeutics and Vaccines industry?

Research Methodology

A unique and promising research methodology forms the base of the market report for the forecast period. This report has been prepared after comprehensive analysis of market events, and riveting insights have been compiled meticulously.

The research methodology is a two-step process comprising primary and secondary research. Key stakeholders, including suppliers, service providers, and experts of several designations, including executive vice presidents, directors, technical advisors, GM marketing professionals, and sales professionals have been interviewed. Secondary sources referred to obtain information include investor presentations of manufacturers, World Bank, IMF, and other credible sources.

The research report includes a competitive landscape that provides a dashboard view of the key competitors operating in the market. Some of the market players included in this section are Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corp., Arrowhead Pharmaceuticals, Inc., BioNTech AG, CureVac AG, Dicerna Pharmaceuticals, Inc., and Regulus Therapeutics, Inc., among others.

Table of Contents

1. Executive Summary

  • 1.1. Market Overview
  • 1.2. Market Analysis
  • 1.3. PMR Analysis and Recommendations

2. Market Introduction

  • 2.1. Market Definition
  • 2.2. Market Taxonomy

3. RNA-based Therapeutics and Vaccines Market Opportunity Analysis

  • 3.1. Macro-Economic Factors
  • 3.2. Opportunity Analysis

4. Market Background

  • 4.1. Regulatory Scenario
  • 4.2. Market Dynamics
    • 4.2.1. Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunity Analysis
  • 4.3. Pipeline Assessment

5. Gross Domestic Product by Region & Country, 2006 - 2021

6. North America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028

  • 6.1. Introduction
  • 6.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
    • 6.2.1. U.S.
    • 6.2.2. Canada
  • 6.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
    • 6.3.1. RNA-based Therapeutics
      • 6.3.1.1. siRNA
      • 6.3.1.2. miRNA
    • 6.3.2. RNA-based Vaccines
      • 6.3.2.1. mRNA
  • 6.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
    • 6.4.1. Oncology
    • 6.4.2. Immunology
    • 6.4.3. Ophthalmology
    • 6.4.4. Cardiovascular Diseases
    • 6.4.5. Infectious Diseases
    • 6.4.6. Genetic Diseases
    • 6.4.7. Others
  • 6.5. Drivers and Restraints - Impact Analysis

7. Latin America RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028

  • 7.1. Introduction
  • 7.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
    • 7.2.1. RNA-based Therapeutics
      • 7.2.1.1. siRNA
      • 7.2.1.2. miRNA
    • 7.2.2. RNA-based Vaccines
      • 7.2.2.1. mRNA
  • 7.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
    • 7.3.1. Oncology
    • 7.3.2. Immunology
    • 7.3.3. Ophthalmology
    • 7.3.4. Cardiovascular Diseases
    • 7.3.5. Infectious Diseases
    • 7.3.6. Genetic Diseases
    • 7.3.7. Others
  • 7.4. Drivers and Restraints - Impact Analysis

8. Europe RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028

  • 8.1. Introduction
  • 8.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
    • 8.2.1. Germany
    • 8.2.2. U.K.
    • 8.2.3. France
    • 8.2.4. Italy
    • 8.2.5. Spain
    • 8.2.6. Russia
    • 8.2.7. Rest of Europe
  • 8.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
    • 8.3.1. RNA-based Therapeutics
      • 8.3.1.1. siRNA
      • 8.3.1.2. miRNA
    • 8.3.2. RNA-based Vaccines
      • 8.3.2.1. mRNA
  • 8.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
    • 8.4.1. Oncology
    • 8.4.2. Immunology
    • 8.4.3. Ophthalmology
    • 8.4.4. Cardiovascular Diseases
    • 8.4.5. Infectious Diseases
    • 8.4.6. Genetic Diseases
    • 8.4.7. Others
  • 8.5. Drivers and Restraints - Impact Analysis

9. Asia Pacific RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028

  • 9.1. Introduction
  • 9.2. Market Size (US$ Mn) Opportunity Assessment By Country, 2022-2028
    • 9.2.1. China
    • 9.2.2. Japan
    • 9.2.3. Australia & New Zealand
    • 9.2.4. Rest of APAC
  • 9.3. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
    • 9.3.1. RNA-based Therapeutics
      • 9.3.1.1. siRNA
      • 9.3.1.2. miRNA
    • 9.3.2. RNA-based Vaccines
      • 9.3.2.1. mRNA
  • 9.4. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
    • 9.4.1. Oncology
    • 9.4.2. Immunology
    • 9.4.3. Ophthalmology
    • 9.4.4. Cardiovascular Diseases
    • 9.4.5. Infectious Diseases
    • 9.4.6. Genetic Diseases
    • 9.4.7. Others
  • 9.5. Drivers and Restraints - Impact Analysis

10. Middle East & Africa RNA-based Therapeutics and Vaccines Opportunity Assessment 2022-2028

  • 10.1. Introduction
  • 10.2. Market Size (US$ Mn) Opportunity Assessment By Product Type, 2022-2028
    • 10.2.1. RNA-based Therapeutics
      • 10.2.1.1. siRNA
      • 10.2.1.2. miRNA
    • 10.2.2. RNA-based Vaccines
      • 10.2.2.1. mRNA
  • 10.3. Market Size (US$ Mn) Opportunity Assessment By Indication Type, 2022-2028
    • 10.3.1. Oncology
    • 10.3.2. Immunology
    • 10.3.3. Ophthalmology
    • 10.3.4. Cardiovascular Diseases
    • 10.3.5. Infectious Diseases
    • 10.3.6. Genetic Diseases
    • 10.3.7. Others
  • 10.4. Drivers and Restraints - Impact Analysis

11. Competition Analysis

  • 11.1. Competition Dashboard

12. Company Profiles

  • 12.1. Company Deep Dive
    • 12.1.1. Alnylam Pharmaceuticals, Inc.
    • 12.1.2. Arbutus Biopharma Corp.
    • 12.1.3. Arrowhead Pharmaceuticals, Inc.
    • 12.1.4. BioNTech AG
    • 12.1.5. CureVac AG
    • 12.1.6. Dicerna Pharmaceuticals, Inc.
    • 12.1.7. Regulus Therapeutics, Inc.
    • 12.1.8. Marina Biotech, Inc.
    • 12.1.9. miRagen Therapeutics
    • 12.1.10. Moderna Therapeutics, Inc.
    • 12.1.11. Quark Pharmaceuticals, Inc.
    • 12.1.12. Santaris Pharma A/S (A Roche Company)
    • 12.1.13. Sylentis S.A.

13. Global RNA-based Therapeutics and Vaccines Market Opportunity Assessment 2022-2028, By Region

  • 13.1. Introduction/Key Findings
  • 13.2. Market Size (US$ Mn) Opportunity Assessment By Region, 2022-2028
    • 13.2.1. North America
    • 13.2.2. Latin America
    • 13.2.3. Europe
    • 13.2.4. Asia Pacific Excluding China
    • 13.2.5. Middle East & Africa
    • 13.2.6. China
  • 13.3. Market Attractiveness Analysis By Region

14. Global Product Opportunity Assessment 2022-2028, By Product Type

  • 14.1. Introduction/Key Findings
  • 14.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Product Type, 2022-2028
    • 14.2.1. RNA-based Therapeutics
      • 14.2.1.1. siRNA
      • 14.2.1.2. miRNA
    • 14.2.2. RNA-based Vaccines
      • 14.2.2.1. mRNA
  • 14.3. Market Attractiveness Analysis By Product Type

15. Global Product Opportunity Assessment 2022-2028, By Indication Type

  • 15.1. Introduction/Key Findings
  • 15.2. Market Size (US$ Mn) and Volume Opportunity Assessment By Indication Type, 2022-2028
    • 15.2.1. Oncology
    • 15.2.2. Immunology
    • 15.2.3. Ophthalmology
    • 15.2.4. Cardiovascular Diseases
    • 15.2.5. Infectious Diseases
    • 15.2.6. Genetic Diseases
    • 15.2.7. Others
  • 15.3. Market Attractiveness Analysis By Indication

16. Global Product Opportunity Assessment 2022-2028

  • 16.1. Market Opportunity Assessment By All Segment
  • 16.2. Absolute $ Opportunity

17. Assumption & Acronyms Used

18. Research Methodology